Literature DB >> 31197692

Resection Versus Observation of Small Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Tumors.

Alex Barenboim1, Guy Lahat1, Ido Nachmany1, Richard Nakache1, Yaakov Goykhman1, Ravit Geva2, Ester Osher3, Erez Scapa4, Ido Wolf2, Lior Orbach1, Eli Brazowski5, Ofer Isakov6, Joseph M Klausner1, Nir Lubezky7.   

Abstract

BACKGROUND: Management of asymptomatic, nonfunctioning small pancreatic neuroendocrine tumors (PNETs) is controversial because of their overall good prognosis, and the morbidity and mortality associated with pancreatic surgery. Our aim was to compare the outcomes of resection with expectant management of patients with small asymptomatic PNETs.
METHODS: Retrospective review of patients with nonfunctioning asymptomatic PNETs < 2 cm that underwent resection or expectant management at the Tel-Aviv Medical Center between 2001 and 2018.
RESULTS: Forty-four patients with small asymptomatic, biopsy-proven low-grade PNETs with a KI67 proliferative index < 3% were observed for a mean of 52.48 months. Gallium67DOTATOC-PET scan was completed in 32 patients and demonstrated uptake in the pancreatic tumor in 25 (78%). No patient developed systemic metastases. Two patients underwent resection due to tumor growth, and true tumor enlargement was evidenced in final pathology in one of them. Fifty-five patients underwent immediate resection. Significant complications (Clavien-Dindo grade ≥ 3) developed in 10 patients (18%), mostly due to pancreatic leak, and led to one mortality (1.8%). Pathological evaluation revealed lymphovascular invasion in 1 patient, lymph node metastases in none, and a Ki67 index ≥ 3% in 5. No case of tumor recurrence was diagnosed after mean follow-up of 52.8 months.
CONCLUSIONS: No patients with asymptomatic low-grade small PNETs treated by expectant management were diagnosed with regional or systemic metastases after a 52.8-month follow-up. Local tumor progression rate was 2.1%. Surgery has excellent long-term outcomes, but it harbors significant morbidity and mortality. Observation can be considered for selected patients with asymptomatic, small, low grade PNETs.

Entities:  

Keywords:  Neuronedocrine tumors; Obervation; Pancreatic resection

Mesh:

Year:  2019        PMID: 31197692     DOI: 10.1007/s11605-019-04285-y

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  9 in total

1.  The Landmark Series: Pancreatic Neuroendocrine Tumors.

Authors:  Jordan M Cloyd; George A Poultsides
Journal:  Ann Surg Oncol       Date:  2020-09-18       Impact factor: 5.344

Review 2.  How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.

Authors:  Francesca Fermi; Valentina Andreasi; Francesca Muffatti; Stefano Crippa; Domenico Tamburrino; Stefano Partelli; Massimo Falconi
Journal:  Curr Oncol Rep       Date:  2022-01-25       Impact factor: 5.075

Review 3.  Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Andrew Canakis; Linda S Lee
Journal:  World J Gastrointest Endosc       Date:  2022-05-16

Review 4.  What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review.

Authors:  Samuel Frey; Eric Mirallié; Maëlle Le Bras; Nicolas Regenet
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

5.  Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives.

Authors:  Elettra Merola; Andrea Michielan; Umberto Rozzanigo; Marco Erini; Sandro Sferrazza; Stefano Marcucci; Chiara Sartori; Chiara Trentin; Giovanni de Pretis; Franca Chierichetti
Journal:  World J Gastrointest Surg       Date:  2022-02-27

6.  Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors.

Authors:  Zheng Zhang; Fei Wang; Zheng Li; Zeng Ye; Qifeng Zhuo; Wenyan Xu; Wensheng Liu; Mengqi Liu; Guixiong Fan; Yi Qin; Yue Zhang; Xuemin Chen; Xianjun Yu; Xiaowu Xu; Shunrong Ji
Journal:  BMC Surg       Date:  2022-05-10       Impact factor: 2.102

7.  Evaluation of Risk Factors for Distant and Lymph Node Metastasis of Pancreatic Neuroendocrine Tumors.

Authors:  Bartosz Molasy; Patryk Zemła; Sławomir Mrowiec; Ewa Grudzińska; Katarzyna Kuśnierz
Journal:  Ther Clin Risk Manag       Date:  2022-07-29       Impact factor: 2.755

8.  Reappraisal of a 2-cm Cutoff Size for the Management of Nonfunctional Pancreatic Neuroendocrine Tumors: A Population-Based Study.

Authors:  Zhen Yang; Dongsheng Zhang; Guangjun Shi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-18       Impact factor: 6.055

9.  Impact of Surgery on Non-Functional Pancreatic Neuroendocrine Tumors ≤2 cm: Analyses With Propensity Score-Based Inverse Probability of Treatment Weighting.

Authors:  Jingyuan Ye; Hongyu Wu; Jinzheng Li; Changan Liu
Journal:  Front Surg       Date:  2022-07-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.